Research and Development Investment: Amgen Inc. vs TG Therapeutics, Inc.

A Decade of R&D Investment: Amgen Inc. vs TG Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Amgen Inc. and TG Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures. Amgen, a titan in the biotech industry, consistently invested heavily, with an average annual R&D expense of approximately $4.2 billion. This commitment peaked in 2021, marking a 35% increase from 2017. In contrast, TG Therapeutics, a smaller player, showed a more dynamic growth trajectory. Starting with modest investments in 2014, TG Therapeutics increased its R&D spending by over 500% by 2021, reflecting its aggressive pursuit of innovation. However, 2023 saw a decline in TG's R&D expenses, possibly indicating a strategic pivot or financial constraints. This comparison underscores the diverse approaches within the biotech sector, where both giants and emerging companies navigate the complex path of innovation.